. Author manuscript; available in PMC: 2019 Jan 11.

Published in final edited form as: Adv Anat Pathol. 2009 Nov;16(6):392–404. doi: 10.1097/PAP.0b013e3181bb6bc2

TABLE 3.

Clinical and Immunophenotypic Features of BPDCN Cases Reviewed at the National Cancer Institute, Bethesda, MD

	Presenting With Cutaneous Involvement	Lacking Cutaneous Involvement at Presentation

Number of patients	46 (84% of total)	9 (16% of total)
Age (y): median, range	67; 4-87	68; 10-84
Male/female, ratio	34/12; 2.8: 1	6/3; 2:1
Prior or concomitant myeloid neoplasia	4/46 (9%)	1/9 (11%)
Immunophenotype
CD4	39/39 (100%)	8/8 (100%)
CD56	44/45 (98%)	9/9 (100%)
CD123	32/32 (100%)	7/7 (100%)
TdT	22/41 (54%)	6/7 (86%)
S-100	6/18 (33%)	1/5 (20%)
CD3	0/38 (0%)	0/9 (0%)
CD34	0/17 (0%)	0/4 (0%)
CD117	0/16 (0%)	0/4 (0%)

BPDCN indicates blastic plasmacytoid dendritic cell neoplasm; TdT, terminal deoxynucleotidyl transferase.